In conclusion, bromocriptine therapy in T2DM patients on high-dose insulin and with poor glycemic control improved glycemic control and meal tolerance while simultaneously allowing for a reduction in the daily insulin dose requirement. Here, INS is linked to type 2 diabetes mellitus.